Kailera Therapeutics Completes IPO
Analysis based on 8 articles · First reported Apr 16, 2026 · Last updated Apr 20, 2026
The successful initial public offering of Kailera Therapeutics, raising $718.8 million, provides significant capital for the company's operations and research in obesity care, potentially boosting investor confidence in the biotechnology sector. The listing on Nasdaq-100 Global Select Market offers new investment opportunities for market participants.
Kailera Therapeutics, an advanced clinical-stage biotechnology company, successfully completed its initial public offering (IPO). The company priced its offering of 39,062,500 shares of common stock at $16.00 per share, initially expecting gross proceeds of $625.0 million. The underwriters, including JPMorgan Chase, Jefferies, Leerink Partners, Toronto-Dominion Bank — TD Cowen, Evercore, and William Blair & Company, fully exercised their option to purchase an additional 5,859,375 shares. This brought the total shares offered to 44,921,875 and the aggregate gross proceeds to $718.8 million. Kailera Therapeutics's common stock began trading on the Nasdaq-100 Global Select Market under the ticker symbol 'KLRA' on April 17, 2026, with the offering officially closing on April 20, 2026. A registration statement for the offering was filed with the United States — United States Securities and Exchange Commission and became effective on April 16, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard